TY - JOUR
T1 - Conversion from intravenous insulin to subcutaneous insulin after cardiovascular surgery
T2 - Transition to target study
AU - Shomali, Mansur E.
AU - Herr, Daniel L.
AU - Hill, Peter C.
AU - Pehlivanova, Marieta
AU - Sharretts, John M.
AU - Magee, Michelle F.
PY - 2011/2/1
Y1 - 2011/2/1
N2 - Background: No study of transition from intravenous to subcutaneous insulin after cardiac surgery with dose based on percentage of intravenous total daily insulin (TDI) has reported a clearly superior regimen for achieving target blood glucose. We compared three first-dose transition strategies for insulin glargine: two based on TDI alone and one that also took body weight into account. Methods: Mostly obese, type 1 and type 2 diabetes patients (n = 223) undergoing cardiac surgery were randomized to receive insulin glargine subcutaneously at 60% or 80% of TDI or in a dose based on TDI and body weight. Results: Transition to subcutaneous insulin occurred 27.4 ± 6.6?h after surgery. Over the study period, mean proportion of blood glucose values within target range (80-140?mg/dL) were 0.34 ± 0.24, 0.35 ± 0.24, and 0.36 ± 0.22 in the 60% TDI, 80% TDI, and weight-based groups, respectively. This difference was not significant. Significantly more insulin corrections were needed in the 60% TDI group than in the weight-based group. There was only one incidence of hypoglycemia (blood glucose <40?mg/dL). Conclusions: No subcutaneous insulin regimen implemented approximately 1 day after cardiac surgery showed significantly better control of blood glucose over the 3-day study period. Further studies are needed to determine optimal formulae for effecting an early transition to subcutaneous insulin after cardiac surgery or whether it is preferable and/or necessary to continue intravenous insulin therapy for an additional period of time.
AB - Background: No study of transition from intravenous to subcutaneous insulin after cardiac surgery with dose based on percentage of intravenous total daily insulin (TDI) has reported a clearly superior regimen for achieving target blood glucose. We compared three first-dose transition strategies for insulin glargine: two based on TDI alone and one that also took body weight into account. Methods: Mostly obese, type 1 and type 2 diabetes patients (n = 223) undergoing cardiac surgery were randomized to receive insulin glargine subcutaneously at 60% or 80% of TDI or in a dose based on TDI and body weight. Results: Transition to subcutaneous insulin occurred 27.4 ± 6.6?h after surgery. Over the study period, mean proportion of blood glucose values within target range (80-140?mg/dL) were 0.34 ± 0.24, 0.35 ± 0.24, and 0.36 ± 0.22 in the 60% TDI, 80% TDI, and weight-based groups, respectively. This difference was not significant. Significantly more insulin corrections were needed in the 60% TDI group than in the weight-based group. There was only one incidence of hypoglycemia (blood glucose <40?mg/dL). Conclusions: No subcutaneous insulin regimen implemented approximately 1 day after cardiac surgery showed significantly better control of blood glucose over the 3-day study period. Further studies are needed to determine optimal formulae for effecting an early transition to subcutaneous insulin after cardiac surgery or whether it is preferable and/or necessary to continue intravenous insulin therapy for an additional period of time.
UR - http://www.scopus.com/inward/record.url?scp=79551582827&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551582827&partnerID=8YFLogxK
U2 - 10.1089/dia.2010.0124
DO - 10.1089/dia.2010.0124
M3 - Article
C2 - 21284478
AN - SCOPUS:79551582827
SN - 1520-9156
VL - 13
SP - 121
EP - 126
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 2
ER -